Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced glycation end product (age)-injected rats

International Journal of Tissue Reactions

Volumn 27, Issue 3, 2005, Pages 137-143

  Yamagishi, S ^a   Takeuchi, M ^b   Inoue, H ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AZELNIDIPINE; CALCIUM ANTAGONIST; DIHYDROPYRIDINE DERIVATIVE; N ACETYL BETA GLUCOSAMINIDASE; SERUM ALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DRUG MECHANISM; GLOMERULOSCLEROSIS; HYPERTENSION; KIDNEY FAILURE; KIDNEY INJURY; MALE; NONHUMAN; RAT; RENAL PROTECTION; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

ACETYLGLUCOSAMINE; ANIMALS; AZETIDINECARBOXYLIC ACID; BLOOD PRESSURE; CALCIUM; DIHYDROPYRIDINES; GLYCOSYLATION END PRODUCTS, ADVANCED; KIDNEY DISEASES; MALE; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN; TIME FACTORS;

ANIMALIA;

EID: 28444481059     PISSN: 02500868     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Friedman E.A. Diabetic renal disease. In: Lifkin H., Porte D. (Eds.). "Ellenberg and Rifkin's Diabetes Mellitus. Theory and Practice." Elsevier, New York, 1990, p. 684.
2. Yamagishi S., Takeuchi M., Makita Z. Advanced glycation end products and the pathogenesis of diabetic nephropathy. Contrib. Nephrol., 134, 30, 2001.
3. Yamagishi S., Inagaki Y., Amano S., et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J. Biol. Chem., 277, 20309, 2002.
4. Yamagishi S., Inagaki Y., Okamoto T., Amano S., Koga K., Takeuchi M. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-β overexpression in proximal tubular cells. Kidney Int., 63, 464, 2003.
5. Brownlee M. Advanced protein glycosylation in diabetes and aging. Ann. Rev. Med., 46, 223, 1995.
6. Bierhaus A., Hofmann M.A., Ziegler R., Nawroth P.P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc. Res., 37, 586, 1998.
7. Schmidt A.M., Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr. Atheroscler. Rep., 2, 430, 2002.
8. Stitt A.W., Li Y.M., Gardiner T.A., et al. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and AGE-infused rats. Am. J. Pathol., 150, 523, 1997.
9. Yamagishi S., Takeuchi M., Inagaki Y., Nakamura K., Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int. J. Clin. Pharm. Res., 23, 129, 2003.
10. Yamagishi S., Hsu C.C., Taniguchi M., et al. Receptor-mediated toxicity to pericytes of advanced glycosylation end products: A possible mechanism of pericyte loss in diabetic microangiopathy. Biochem. Biophys. Res. Commun., 213, 68, 1995.
11. Yamagishi S., Amano S., Inagaki Y., et al. Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem. Biophys. Res. Commun., 290, 973, 2002.
12. Yamagishi S., Inagaki Y., Amano S., et al. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem. Biophys. Res. Commun., 296, 877, 2002.
13. Yamagishi S., Okamoto T., Amano S., et al. Palmitate-induced apoptosis of microvascular endothelial cells and pericytes. Mol. Med., 8, 178, 2002.
14. Tanaka N., Yonekura H., Yamagishi S., et al. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J. Biol. Chem., 275, 25781, 2000.
15. 2 analogue, protects against advanced glycation end products-induced injury in cultured retinal pericytes. Mol. Med., 8, 547, 2002.
16. Yamagishi S., Yamamoto Y., Harada S., Hsu C.C., Yamamoto H. Advanced glycosylation end products stimulate the growth but inhibit the prostacyclin-producing ability of endothelial cells through interactions with their receptors. FEBS Lett., 384, 103, 1996.
17. Yamagishi S., Yonekura H., Yamamoto Y., et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J. Biol. Chem., 272, 8723, 1997.
18. Yamagishi S., Fujimori H., Yonekura H., Yamamoto Y., Yamamoto H. Advanced glycation end products inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia, 41, 1435, 1998.
19. Okamoto T., Yamagishi S., Inagaki Y., et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J., 16, 1928, 2002.
20. Inagaki Y., Yamagishi S., Okamoto T., Takeuchi M., Amano S. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia, 46, 284, 2003.
21. Forbes J.M., Cooper M.E., Oldfield M.D., Thomas M.C. Role of advanced glycation end products in diabetic nephropathy. J. Am. Soc. Nephrol., 14, S254, 2003.
22. Metz T.O., Alderson N.L., Thorpe S.R., Baynes J.W. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: A novel therapy for treatment of diabetic complications. Arch. Biochem. Biophys., 419, 41, 2003.
23. El-Atat F., McFarlane S.I., Sowers J.R. Diabetes, hypertension, and cardiovascular derangements: Pathophysiology and management. Curr. Hypertens. Rep., 6, 215, 2004.
24. Luno J., Garcia de Vinuesa S., Gomez-Campdera F., Lorenzo I., Valderrabano F. Effects of antihypertensive therapy on progression of diabetic nephropathy Kidney Int., 68, S112, 1998.
25. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br. Med. J., 317, 703, 1998.
26. Kuramoto K., Ichikawa S., Hirai A., et al. Azelnidipine and amlodipine: A comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens. Res., 26, 201, 2003.
27. Yamagishi S., Inagaki Y., Nakamura K., Imaizumi T. Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J. Cardiovasc. Pharmacol., 43, 724, 2004.
28. Koga K., Yamagishi S., Takeuchi M., et al. CS-866, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty rats. Mol. Med., 8, 591, 2002.
29. Yamagishi S., Koga K., Inagaki Y., Amano S., Okamoto T., Takeuchi M. Dilazep hydrochloride, an antiplatelet drug, prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty rats. Drugs Exptl. Clin. Res., 28, 221, 2002.
30. Raij L., Azar S., Keane W. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int., 26, 137, 1984.
31. Saito T., Sumithraum E., Glasgow E.F., Atkins R.C. The enhancement of aminonucleoside nephrosis by the co-administration of proamine. Kidney Int., 32, 691, 1987.
32. Nakamura T., Obata J., Kimura H., et al. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int., 55, 877, 1999.
33. Vlassara H., Striker L.J., Teichberg S., Fuh H., Li Y.M., Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc. Natl. Acad. Sci. USA., 91, 11704, 1994.
34. Chakravarthy U., Hayes R.G., Stitt A.W., McAuley E., Archer U.S. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes, 47, 945, 1998.
35. Xu B., Chibber R., Ruggiero D., et al. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J., 17, 1289, 2003.
36. Bucala R., Tracey K.J., Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Invest., 87, 432, 1991.
37. Mizutani K., Ikeda K., Tsuda K., Yamori Y. Inhibitor for advanced glycation end products formation attenuates hypertension and oxidative damage in genetic hypertensive rats. J. Hypertens., 20, 1607, 2002.
38. Taft J., Nolan C.J., Yeung S.P., et al. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes, 43, 1046, 1994.
39. Ziyadeh F.N., Goldfarb S. The renal tubulointerstitium in diabetes mellitus. Kidney Int., 39, 464, 1991.
40. Gilbert R.E., Cooper M.E. The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int., 56, 1627, 1999.
41. Wautier M.P., Chappey O., Corda S., et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab., 280, 685, 2001.